Regulatory Story
Company Consort Medical PLC
Headline Notice of Results
Released 16:30 21-May-2019
Number 7498Z

RNS Number : 7498Z
Consort Medical PLC
21 May 2019

21 May 2019


Consort Medical plc


Notice of Results


Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global, single source drug and delivery device company, will announce its financial results for the year ended 30 April 2019 on Thursday, 13 June 2019.




Consort Medical

Tel: +44 (0) 1442 867920

Jonathan Glenn - Chief Executive Officer

Paul Hayes - Chief Financial Officer

FTI Consulting

Tel: +44 (0) 20 3727 1000

Ben Atwell / Simon Conway


About Consort Medical

Consort Medical plc is a leading one-stop developer and manufacturer of drugs and premium drug delivery devices. We partner with pharmaceutical businesses in providing innovative life improving treatments to patients across the world through two integrated activities:


The design, development and manufacture of high performance medical devices for inhaled, injectable, nasal and ocular drug delivery, as well as point-of-care diagnostics products.


The development, formulation and manufacture of active pharmaceutical ingredients (APIs) and finished dose drugs to the highest quality standards.


We employ over 2,000 people globally and are committed to investing in patient, clinician and customer driven innovation to create new treatments.


Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT) and is organised in two divisions: Bespak and Aesica.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.